scholarly journals The role of HLA antibodies in allogeneic SCT: is the ‘type-and-screen’ strategy necessary not only for blood type but also for HLA?

2012 ◽  
Vol 47 (12) ◽  
pp. 1499-1506 ◽  
Author(s):  
S Yoshihara ◽  
K Taniguchi ◽  
H Ogawa ◽  
H Saji
Keyword(s):  
Blood Type ◽  
Hla Antibodies ◽  
Screen Strategy

scholarly journals Immune Checkpoints Expression in Chronic Lung Allograft Rejection

2021 ◽  
Vol 12 ◽  
Author(s):  
Ilaria Righi ◽  
Valentina Vaira ◽  
Letizia Corinna Morlacchi ◽  
Giorgio Alberto Croci ◽  
Valeria Rossetti ◽  
...  
Keyword(s):  
T Lymphocytes ◽  
Bronchiolitis Obliterans Syndrome ◽  
Immune Checkpoints ◽  
Hla Antibodies ◽  
Restrictive Allograft Syndrome ◽  
And Function ◽  
Shed Light

Chronic lung allograft dysfunction (CLAD) is the main cause of poor survival and low quality of life of lung transplanted patients. Several studies have addressed the role of dendritic cells, macrophages, T cells, donor specific as well as anti-HLA antibodies, and interleukins in CLAD, but the expression and function of immune checkpoint molecules has not yet been analyzed, especially in the two CLAD subtypes: BOS (bronchiolitis obliterans syndrome) and RAS (restrictive allograft syndrome). To shed light on this topic, we conducted an observational study on eight consecutive grafts explanted from patients who received lung re-transplantation for CLAD. The expression of a panel of immune molecules (PD1/CD279, PDL1/CD274, CTLA4/CD152, CD4, CD8, hFoxp3, TIGIT, TOX, B-Cell-Specific Activator Protein) was analyzed by immunohistochemistry in these grafts and in six control lungs. Results showed that RAS compared to BOS grafts were characterized by 1) the inversion of the CD4/CD8 ratio; 2) a higher percentage of T lymphocytes expressing the PD-1, PD-L1, and CTLA4 checkpoint molecules; and 3) a significant reduction of exhausted PD-1-expressing T lymphocytes (PD-1pos/TOXpos) and of exhausted Treg (PD-1pos/FOXP3pos) T lymphocytes. Results herein, although being based on a limited number of cases, suggest a role for checkpoint molecules in the development of graft rejection and offer a possible immunological explanation for the worst prognosis of RAS. Our data, which will need to be validated in ampler cohorts of patients, raise the possibility that the evaluation of immune checkpoints during follow-up offers a prognostic advantage in monitoring the onset of rejection, and suggest that the use of compounds that modulate the function of checkpoint molecules could be evaluated in the management of chronic rejection in LTx patients.

Transfusion-Related Acute Lung Injury Secondary to Biologically Active Mediators

2001 ◽  
Vol 125 (4) ◽  
pp. 523-526
Author(s):  
Susan E. Lenahan ◽  
Ronald E. Domen ◽  
Christopher C. Silliman ◽  
Charles P. Kingsley ◽  
Paula J. Romano
Keyword(s):  
Acute Lung Injury ◽  
Lung Injury ◽  
Distress Syndrome ◽  
Biologically Active ◽  
Blood Components ◽  
Hla Antibodies ◽  
Granulocyte Antibodies ◽  
Priming Activity ◽  
Stored Blood

Abstract Transfusion-related acute lung injury is seen following the transfusion of blood components. The reported incidence is approximately 1 in 2000 transfusions. Clinically, it is similar to adult respiratory distress syndrome. The pathophysiology is unclear but has been attributed to HLA antibodies, granulocyte antibodies, and more recently to biologically active mediators in stored blood components. We report a case with laboratory evidence that supports the role of biologically active mediators in the pathogenesis of transfusion-related acute lung injury. To our knowledge, the case reported here is the first to use lipid extractions of patient samples to determine that lipid-priming activity was present at the time transfusion-related acute lung injury was identified clinically.

P193 The role of low donor specific HLA antibodies in ABO incompatible renal transplantation

2019 ◽  
Vol 80 ◽  
pp. 208
Author(s):  
Reem Mousali ◽  
Najla Zabani ◽  
Wael Habhab ◽  
Nabeela AlBaz ◽  
Osama Alsuraihi ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Hla Antibodies

Exploring the Role of Non-HLA Antibodies in Primary Graft Dysfunction After Cardiac Transplantation

2015 ◽  
Vol 34 (4) ◽  
pp. S302-S303
Author(s):  
P. Shah ◽  
A.M. Jackson ◽  
M.C. Philogene ◽  
S.S. Desai ◽  
N.A. Burton ◽  
...  
Keyword(s):  
Cardiac Transplantation ◽  
Primary Graft Dysfunction ◽  
Graft Dysfunction ◽  
Hla Antibodies

scholarly journals Clinical Relevance of HLA Antibodies in Kidney Transplantation: Recent Data from the Heidelberg Transplant Center and the Collaborative Transplant Study

2017 ◽  
Vol 2017 ◽  
pp. 1-7 ◽  
Author(s):  
Caner Süsal ◽  
Alexander Fichtner ◽  
Burkhard Tönshoff ◽  
Arianeb Mehrabi ◽  
Martin Zeier ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Immune System ◽  
High Risk ◽  
Clinical Relevance ◽  
Clinical Routine ◽  
Hla Antibodies ◽  
Transplant Center ◽  
T Cell Help ◽  
Harmful Effects

Herein, we summarize our recent findings from the international Collaborative Transplant Study (CTS) and Heidelberg Transplant Center regarding the role of HLA antibodies in kidney transplantation and their application into the clinical routine. Based on the antibody findings from the CTS serum study, an algorithm was developed in 2006 for the transplantation of high-risk sensitized patients at the Heidelberg Transplant Center which includes seven different pre- and posttransplant measures. Using this algorithm, the number of transplantations could be increased in high-risk presensitized patients and the previously existing impact of antibodies on graft survival could greatly be diminished but not totally eliminated. More recent findings led to the hypothesis that T cell help from a preactivated immune system supports the harmful effects of pretransplant donor-specific HLA antibodies that otherwise disappear in many cases after transplantation without any consequence.

A Reevaluation of the Role of IgM Non-HLA Antibodies in Cardiac Transplantation

2009 ◽  
Vol 87 (6) ◽  
pp. 864-871 ◽  
Author(s):  
John D. Smith ◽  
Iman M. Hamour ◽  
Margaret M. Burke ◽  
Balikrishnan Mahesh ◽  
Rachel E. Stanford ◽  
...  
Keyword(s):  
Cardiac Transplantation ◽  
Hla Antibodies

scholarly journals The Milk Metabolome of Non-secretor and Lewis Negative Mothers

2021 ◽  
Vol 7 ◽  
Author(s):  
Aidong Wang ◽  
Petya Koleva ◽  
Elloise du Toit ◽  
Donna T. Geddes ◽  
Daniel Munblit ◽  
...  
Keyword(s):  
Human Milk ◽  
Free Amino ◽  
Principal Component ◽  
Blood Type ◽  
Research Report ◽  
Change Analysis ◽  
Milk Samples ◽  
Lactating Mothers ◽  
Fold Change Analysis

Introduction: The functional role of milk for the developing neonate is an area of great interest, and a significant amount of research has been done. However, a lot of work remains to fully understand the complexities of milk, and the variations imposed through genetics. It has previously been shown that both secretor (Se) and Lewis blood type (Le) status impacts the human milk oligosaccharide (HMO) content of human milk. While some studies have compared the non-HMO milk metabolome of Se+ and Se− women, none have reported on the non-HMO milk metabolome of Se− and Le– mothers.Method and Results: To determine the differences in the non-HMO milk metabolome between Se–Le– mothers and other HMO phenotypes (Se+Le+, Se+Le–, and Se–Le+), 10 milk samples from 10 lactating mothers were analyzed using nuclear magnetic resonance (NMR) spectroscopy. Se or Le HMO phenotypes were assigned based on the presence and absence of 6 HMOs generated by the Se and Le genes. After classification, 58 milk metabolites were compared among the HMO phenotypes. Principal component analysis (PCA) identified clear separation between Se–Le– milk and the other milks. Fold change analysis demonstrated that the Se–Le– milk had major differences in free fatty acids, free amino acids, and metabolites related to energy metabolism.Conclusion: The results of this brief research report suggest that the milk metabolome of mothers with the Se–Le– phenotype differs in its non-HMO metabolite composition from mothers with other HMO phenotypes.

ABO blood group and the risk of breast cancer: Multicenter, case-control, observational study.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1572-1572
Author(s):  
Yuksel Urun ◽  
Tulay Koru-Sengul ◽  
Kadri Altundag ◽  
Gungor Utkan ◽  
Handan Onur ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Blood Group ◽  
Blood Groups ◽  
Blood Type ◽  
Abo Blood Group ◽  
Abo Blood Groups ◽  
Blood Types ◽  
Abo Blood Type

1572 Background: The role of genetic factors in the development of cancer is widely accepted. ABO blood type is an inherited characteristic and previous studies have observed an association between ABO blood group and risk of certain malignancies, including pancreatic and gastric cancer. The data on the role of ABO blood group and Rh factor in breast cancer is inconclusive. Methods: All patients who had breast cancer (BC) and treated between 2000-2010 at the Departments of Medical Oncology of both Ankara and Hacettepe Universities (Ankara, Turkey) with defined ABO blood type and Rh factor were included in our retrospective reviews of tumor registry records. A group of volunteer healthy women donors of Turkish Red Crescent between 2004-2011 were identified as a control group, without any matching factors. The relationship of ABO blood types and Rh factor with various prognostic factors such as age at diagnosis, menopausal status, family history of breast cancer, and ER/PR/HER2 status were evaluated from 1740 BC patients. We compared the distributions of ABO blood types, Rh factors among 1740 patients and 204,553 healthy controls. Among BC patients, differences between each of aforementioned ABO blood groups and Rh factors with respect to various prognostic factors were explored, respectively. Results: Overall distributions of ABO blood groups as well as Rh factor were comparable between patients (44% A, 8% AB, 16% B, 32% O, 88% Rh+) and controls (41% A, 8% AB, 16% B, 35% O, 87% Rh+). However, there were statistically significant differences between patients and controls with respect to A vs. nonA (p=0.019) and marginal significance (p=0.051) for O vs. nonO. Among patients, there were statistically significant differences between A and nonA with respect to HER2 (p=0.0421), M stage (p=0.0447), T stage (p=0.0020). Only T stage (p=0.0337) were significantly different between O vs nonO. Grade (p=0.0227) and M stage (p=0.0107) were significantly different between Rh factors. Conclusions: In our study sample, ABO blood type was statistically significantly associated with breast cancer. Additional studies are necessary to determine the mechanisms by which ABO blood type may influence the risk of breast cancer.

Role of C1q-binding donor-specific anti-HLA antibodies in Premature and Accelerated Kidney Allograft Interstitial Fibrosis

2018 ◽  
Vol 102 ◽  
pp. S276
Author(s):  
Kevin Louis ◽  
Denis Viglietti ◽  
Olivier Aubert ◽  
Alexandre Loupy ◽  
Carmen Lefaucheur
Keyword(s):  
Interstitial Fibrosis ◽  
Hla Antibodies ◽  
Kidney Allograft
Sign in / Sign up

Export Citation Format

Share Document